Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood pressure
Biotech
AstraZeneca's $1.3B bet yields 2nd phase 3 blood pressure win
The phase 3 win for baxdrostat boost AstraZeneca's attempts to turn the molecule’s long half-life into a competitive advantage.
Nick Paul Taylor
Oct 7, 2025 4:01am
FDA warns against unreviewed blood pressure tech, baby monitors
Sep 17, 2025 12:00pm
Apple aims to catch 1M hypertension cases with new Apple Watch
Sep 10, 2025 10:30am
AstraZeneca gears up for baxdrostat FDA filing after ph. 3 win
Sep 1, 2025 6:13am
New blood pressure guidelines include renal denervation
Aug 18, 2025 3:15pm
Orchestra BioMed scores $111M, backed by Medtronic, Ligand
Aug 5, 2025 3:41pm